QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Arcturus Therapeutics Holdings Inc. (ARCT)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3 (the strategy requires both >= 3 before any bullish entry); the chart is bearish anyway - price 8.36 sits below SMA50 12.43 with MACD -0.92 < 0, so a pullback/oversold limit would also fail the trend-alignment gate, and no breakout stop qualifies with price under every average.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Arcturus Therapeutics Holdings Inc. is a biotechnology company developing RNA-based medicines, including vaccines for infectious diseases and treatments for rare liver and respiratory conditions. Key programs include LUNAR-OTC for ornithine transcarbamylase deficiency and LUNAR-CF for cystic fibrosis.

Fundamental

weak
Fundamental2
Weak fundamentals

Arcturus Therapeutics shows operational deterioration with significant revenue decline and negative intrinsic value.

Operationally deteriorating but balance-sheet-stable pre-profit mRNA biotech. Revenue has fallen from $157.7M in FY2023 to $24.9M trailing twelve months after the CSL Seqirus collaboration was terminated in August 2026, GAAP losses continue at roughly $87M with about $62M of annual operating cash burn, and both DCF models return negative per-share values. The offsets are $184.8M of cash, no interest-bearing debt, no going-concern conclusion and no maturity wall. Weak and inconsistent financials with elevated risk - a watchlist name, not an actionable investment.

Sentiment

weak
Sentiment2
Neutral sentiment

Sentiment is neutral with no significant catalysts or sentiment improvement in the near term.

The dominant near-term driver is the already-released Q3 2026 print (2026-11-05, announced confidence), and the in-window media cluster scored it essentially flat at roughly +0.07 across five scored items because an optical revenue beat carried by a $12.0M CSL Seqirus termination payment was offset by an EPS miss and cautious coverage. The sentiment delta is indeterminate on the sparse-baseline rule (only two unique on-topic baseline items despite constructively-covered September news), retail is indeterminate because Reddit access was blocked outright, and the Red-Flag Screen is clean — leaving post-earnings digestion of a neutral, poor-quality print with no forward catalyst inside the 30-day horizon.

Technical

very weak
Technical1
Bearish trend

The stock is in a downtrend, with price below all key moving averages and weak momentum indicators.

Price 8.36 sits below every moving average in the stack (SMA20 10.20, SMA50 12.43, SMA200 9.10, EMA9 9.36, EMA21 10.26, WMA9 9.17, WMA21 9.87, DEMA14 8.79, TEMA14 8.63) after a five-session slide of roughly 28% (10.35 -> 8.36). MACD line -0.92 is below its signal -0.79 with the histogram widening to -0.13, and RSI14 36.96 / Williams %R -94.44 show momentum that is weak and not repairing. ADX14 19.08 confirms the move lacks trend acceleration, so this is a broken, drifting downtrend rather than a coiled base - chart score 1. Independently, fundamentalScore 2 and qualitativeScore 2 both fall below the required floor of 3, so the trade plan is hard-blocked regardless of the chart read.

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.